Radioiodine Therapy in Patient with Differentiated Thyroid Cancer and Chronic Kidney Disease on Maintenance Hemodialysis: First Case of Bangladesh

نویسندگان

چکیده

The conventional course of differentiated thyroid cancer (DTC) treatment requires surgical resection followed by radioactive iodine (131I) therapy (RAIT). Patients are advised to drink plenty water, as 131I gets eliminated through the kidneys and burden extra radiation is reduced. Treating a case DTC with chronic kidney disease (CKD) RAIT challenging. As result, when planning hemodialysis in patient CKD, dose 131I, timing dialysis, safety must all be carefully considered. Because dialyzable, standard Geiger counter can observe detect it. A post-thyroidectomized CKD was successfully treated while continuing scheduled peritoneal (HD) simultaneously during hospital isolation, reported here. This report aimed at sharing HD management procedures, challenges any adverse effects, exposure doses 131I-treated patients their immediate post-ablative days. measurements after following 131 I administration revealed levels less than 4.20 Sv/h on fifth day, allowing safe discharge this case. Bangladesh J. Nuclear Med. 26(1): 71-74, 2023

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Radioiodine therapy effects on salivary gland function in patients with differentiated thyroid cancer [Persian]

Salivary gland involvement is one of the radioiodine therapy complications. Salivary gland scintigraphy in quantitative mode can accurately evaluate salivary gland function. Methods: Salivary gland scintigraphy was performed with Tc-99m Pertechnetate, at the time of iodine therapy as a basic study and then 3 weeks and 3 months afterwards. Ejection Fraction (EF) of parotid and submandibula...

متن کامل

Radioiodine Therapy in Differentiated Thyroid Cancer

For many years the recommended therapy for differentiated thyroid carcinoma (DTC), with the exception of unifocal papillary carcinoma <1 cm in diameter, has consisted of (near) total thyroidectomy followed by postoperative radioiodine ablation of thyroid remnant tissue. Even though results from randomized controlled trials are still missing, this combination has proven its worth as a safe and v...

متن کامل

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease

Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients that recur often require surgery and further radioactive iodine to render them disease-free. Five percent of thyroid cancer patients, however, will eventually succumb to their disease. Metastatic thyroid cancer is treated with radioactive iodine if the metastases are ...

متن کامل

radioiodine therapy effects on salivary gland function in patients with differentiated thyroid cancer [persian]

salivary gland involvement is one of the radioiodine therapy complications. salivary gland scintigraphy in quantitative mode can accurately evaluate salivary gland function. methods: salivary gland scintigraphy was performed with tc-99m pertechnetate, at the time of iodine therapy as a basic study and then 3 weeks and 3 months afterwards. ejection fraction (ef) of parotid and submandibular glan...

متن کامل

Incidentally polycystic kidney disease identified by SPECT/CT with post-therapy radioiodine scintigraphy in a patient with differentiated thyroid carcinoma

RATIONALE Post-therapy or diagnostic whole-body radioiodine scintigraphy is widely employed to evaluate the residual, recurrence, or metastases of differentiated thyroid carcinoma because of the high sensitivity and accuracy. However, it has pitfalls. PATIENT CONCERNS We described a 63-year-old male with a history of papillary thyroid carcinoma who was referred for iodine-131 ablation therapy...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Bangladesh journal of nuclear medicine

سال: 2023

ISSN: ['1562-3831']

DOI: https://doi.org/10.3329/bjnm.v26i1.64671